Hemostatic system in patients with endometrial hyperplasia and the risk of venous thrombosis: А literature review
- Authors: Ozolinya L.A.1, Anikeeva A.A.1
-
Affiliations:
- N.I. Pirogov Russian National Research Medical University
- Issue: Vol 9, No 4 (2022)
- Pages: 193-201
- Section: Literature reviews
- URL: https://journal-vniispk.ru/2313-8726/article/view/120399
- DOI: https://doi.org/10.17816/2313-8726-2022-9-4-193-201
- ID: 120399
Cite item
Full Text
Abstract
While treating patients with endometrial hyperplasia, the physician may face both bleeding and thrombotic complications, particularly, during hormonal or surgical treatment, which significantly increases the risk of these complications. In addition, thrombotic complications in gynecological patients may result from congenital or acquired thrombophilia, blood flow disorders (blood stasis), and vascular wall damage, that is, the classic Virchow triad.
This study aimed to review the recent scientific literature on the peculiarities of the blood coagulation system in patients with endometrial hyperplasia.
The review reflects the results of studies conducted by Russian and foreign authors on the status of the blood coagulation system in patients with endometrial hyperplasia. The features of vascular, thrombocytic, plasma (procoagulant and anticoagulant), and fibrinolytic elements of hemostasis in these patients are considered. The data from the literature on the state of hemostasis before treatment and following hormone therapy and surgical treatment are presented. Moreover, the data of some studies on the genetic features of the hemostatic system in patients with endometrial hyperplasia are summarized. An analysis of the literature indicates the need for a careful choice of drugs and methods of treatment of these patients to avoid venous thromboembolic complications.
Full Text
##article.viewOnOriginalSite##About the authors
Lyudmila A. Ozolinya
N.I. Pirogov Russian National Research Medical University
Author for correspondence.
Email: ozolinya@yandex.ru
ORCID iD: 0000-0002-2353-123X
SPIN-code: 9407-9014
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowAngelina A. Anikeeva
N.I. Pirogov Russian National Research Medical University
Email: angel-1609@mail.ru
ORCID iD: 0000-0002-5754-7563
student
Russian Federation, MoscowReferences
- Cree IA, White VA, Indave BI, Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020;76(1):151–156. doi: 10.1111/his.13977
- Salamova KK, Saprykina LV, Ramazanova AM, et al. Clinical characteristics of women with endometrial hyperplasia. Russian Journal of Woman and Child Health. 2021;4(2):124–129. (In Russ). doi: 10.32364/2618-8430-2021-4-2-124-129
- Ozolinja LA, Lapina IA. Rational approaches to the prevention of vascular complications in patients with endometrial hyperplasia. Gynecology. 2014;16(3):53–56 (In Russ).
- Ozolinya LA, Kerchelaeva SB, Lapina IA, Makarov OV. Venous thromboembolic complications in obstetrics and gynecology. 2nd ed., revis. and expand. Moscow: GEOTAR-Media; 2020. 288 p. (In Russ). doi: 10.33029/9704-5651-4-VTO-2020-1-288 5.
- Cakmak B, Gulucu S, Aliyev N, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios in endometrial hyperplasia. Obstet Gynecol Sci. 2015;58(2):157–161. doi: 10.5468/ogs.2015.58.2.157
- Karateke A, Kaplanoglu M, Baloglu A. Relations of Platelet Indices with Endometrial Hyperplasia and Endometrial Cancer. Asian Pac J Cancer Prev. 2015;16(12):4905–4908. doi: 10.7314/apjcp.2015.16.12.4905
- Yayla Abide C, Bostanci Ergen E, Cogendez E, et al. Evaluation of complete blood count parameters to predict endometrial cancer. J Clin Lab Anal. 2018;32(6):e22438. doi: 10.1002/jcla.22438
- Acmaz G, Aksoy H, Unal D, et al. Are neutrophil/lymphocyte and platelet/lymphocyte ratios associated with endometrial precancerous and cancerous lesions in patients with abnormal uterine bleeding? Asian Pac J Cancer Prev. 2014;15(4):1689–1692. doi: 10.7314/apjcp.2014.15.4.1689
- Ural ÜM, Şehitoğlu İ, Tekin YB, Şahin FK. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with endometrial hyperplasia and endometrial cancer. J Obstet Gynaecol Res. 2015;41(3):445–448. doi: 10.1111/jog.12536
- Senchuk A, Pokrovenko O. Modern aproaches to the choice of treatment of hyperplastic diseases of endo- and myometrium. Okhrana materinstva i detstva. 2013;(1):64–67. (In Russ).
- Saidova RA, Fedina EV. Investigation of the hemostasis system in women of reproductive age with provisional diagnosis ― endometrial hyperplasia. Journal of New Medical Technologies, eEdition. 2006;13(3):55. (In Russ).
- Fedina EV. Investigation of the hemostasis system for solving the problem of choosing tactics for managing patients with endometrial hyperplastic processes in the reproductive period. Siberian Journal of Oncology. 2007;(S1 suppl.):94–96. (In Russ).
- Plavinskiy SL, Barinova AN, Ozolinya LА. Adverse outcomes of using hormonal drugs. An analysis of pharmacoepidemiological research works and spontaneous reporting databases. Gynecology, Obstetrics and Perinatology. 2019;18(6):92–99. (In Russ). doi: 10.20953/1726-1678-2019-6-92-99
- Gabelova KA, Shabanova NA, Bezhenar VF, Zvartau EE, Akishina YuA. Risks of venous thromboembolic complications in related to combined oral contraceptives. Obstetrics, Gynecology and Reproduction. 2021;15(6):777–787. (In Russ). doi: 10.17749/2313-7347/ob.gyn.rep.2021.207
- Grishenko OV, Bobritskaya VV. The efficacy of hemostasis in gynecological practice. Health of Woman. 2016.10(116):94–97 (In Russ.). doi: 10.15574/HW.2016.116.94
- Snitsarenko EN, Yakovets SM, Andrianova NL. Changes in hemostasis against the background of hormonal treatment of endometrial hyperplasia in reproductive age. Proceedings of the International Scientific and Practical Conference «Sovremennye problemy radiatsionnoi meditsiny: ot nauki k praktike»; 2015 April 24; Gomel. P. 157–158. Available from: https://elibrary.ru/item.asp?id=23824788&ysclid=l97ibdmny300734458 (In Russ).
- Ozolinya LA, Patrushev LI, Lutsenko NN, Patrusheva NL. Endometrial hyperplasia: treatment options, prevention of complications, genotype features. Terra Medica. 2013;(3):50–51. (In Russ).
- Lapina IA, Dobrokhotova YuE, Ozolinya LA, Chirvon TG, Taranov VV. An integrated approach to the management of patients with endometrial hyperplasia and metabolic syndrome. Gynecology. 2021;23(1):55–61. (In Russ). doi: 10.26442/20795696.2021.1.200642
- Seregina PE, Totchiev GF, Panova EA. Prognostic significance of PLA polymorphysm of glicoprotein IIIA gene (GPIIIA) in endometrial hyperplasia. RUDN Journal of Medicine. 2009;(5):154–160. (In Russ).
Supplementary files
